Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 5, 2023 – Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PT in San Francisco, CA.
Investors can access an audio webcast of this presentation on Chimerix's Investor Relations website, where it will be archived for about 90 days. Chimerix focuses on developing medicines that improve the lives of patients with severe diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.
- None.
- None.
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.
An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
CONTACTS:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Nick Lamplough / Dan Moore / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ
When will Chimerix present at the J.P. Morgan Healthcare Conference?
Where can I watch the Chimerix conference presentation?
What is Chimerix's main drug development focus?
What is the stock symbol for Chimerix?
